Last $18.59 USD
Change Today +0.20 / 1.09%
Volume 331.7K
XON On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$18.23
Previous Close
$18.39
Day High
$18.63
Day Low
$18.20
52 Week High
01/21/14 - $38.50
52 Week Low
05/9/14 - $13.13
Market Cap
1.9B
Average Volume 10 Days
493.7K
EPS TTM
$-0.47
Shares Outstanding
100.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and database systems for mapping cellular pathways, as well as its computational modeling and simulation platform; LEAP, a proprietary laser-enabled analysis and processing technology; and mAbLogix, a proprietary antibody discovery platform that enables production of B-cell libraries for discovery of antibodies. It has collaborations with ZIOPHARM Oncology, Inc.; Elanco, Inc.; Fibrocell Science, Inc.; Oragenics, Inc.; Synthetic Biologics, Inc.; AquaBounty Technologies, Inc.; AmpliPhi BioSciences Corp.; Genopaver, LLC; and Soligenix, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in West Palm Beach, Florida.

223 Employees
Last Reported Date: 03/31/14
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Founder and Chief Science Officer
Total Annual Compensation: $499.2K
Chief Operating Officer
Total Annual Compensation: $2.1M
Senior Vice President of Energy & Chemicals S...
Total Annual Compensation: $341.0K
Senior Vice President of Product Development
Total Annual Compensation: $426.1K
Compensation as of Fiscal Year 2013.

intrexon corp (XON) Key Developments

Intrexon Corporation Appoints Keith Canada as Vice President, UltraVector Division, Effective September 15, 2014

Intrexon Corporation announced the appointment of Keith Canada, Ph.D., as Vice President, UltraVector Division, effective September 15, 2014. He will report to Chief Operating Officer Krish Krishnan. Dr. Canada's recruitment coincides with the recent introduction of the BeyondBio(TM) portal, which further expands the accessibility of Intrexon's UltraVector(R) platform to its diverse commercial collaborators. Dr. Canada brings to Intrexon significant experience in the biotechnology and pharmaceutical industries, including 11 years at Boehringer Ingelheim Pharmaceuticals Inc., where he most recently led a global engineering group responsible for high-throughput gene recovery, bioinformatic analysis, optimization, and formatting of novel biotherapeutics.

Intrexon Seeking To Make Acquisitions and Strategic Investment

Intrexon Corporation (NYSE:XON) has made an offering and will use the net proceeds for working capital, financing of capital expenditures, repayment or redemption of existing indebtedness, and future acquisitions and strategic investment opportunities.

Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Intrexon Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenues were $11.8 million for the quarter ended June 30, 2014 compared to $6.7 million for the quarter ended June 30, 2013, an increase of $5.1 million, or 76%. The $5.1 million increase in collaboration revenue resulted primarily from the following: (i) recognition of deferred revenue for upfront payments received from 11 collaborations or expansions thereof signed by Intrexon between July 1, 2013 and June 30, 2014; (ii) recognition of research and development services performed by the Company pursuant to these new collaborations; and (iii) increased research and development services performed by Intrexon for collaborations in effect prior to June 30, 2013 as a result of the progression of current programs and the initiation of new programs with these collaborators. Operating loss was $18.082 million against $14.254 million a year ago. Loss before tax was $53.218 million against $6.519 million a year ago. Net loss attributable to common shareholders was $52.043 million or $0.53 per basic and diluted share against net loss attributable to common shareholders of $13.905 million or $2.45 per basic and diluted share a year ago. LBITDA was $50.364 million against $4.148 million a year ago. Adjusted LBITDA was $10.425 million against $4.504 million a year ago. Pro forma adjusted LBITDA per share diluted was $0.11 against $0.05 a year ago. Total revenues were $19.6 million for the six months ended June 30, 2014 compared to $10.6 million for the six months ended June 30, 2013, an increase of $9.0 million, or 86 percent. The $9.0 million increase in collaboration revenue resulted primarily from the following: (i) recognition of deferred revenue for upfront payments received from 11 collaborations or expansions thereof signed by Intrexon between July 1, 2013 and June 30, 2014; (ii) recognition of research and development services performed by the Company pursuant to these new collaborations; and (iii) increased research and development services performed by Intrexon for collaborations in effect prior to June 30, 2013 as a result of the progression of current programs and the initiation of new programs with these collaborators. Operating loss was $35.954 million against $28.260 million a year ago. Loss before tax was $49.663 million against $42.881 million a year ago. Net loss attributable to common shareholders was $47.928 million or $0.49 per basic and diluted share against net loss attributable to common shareholders of $56.621 million or $10.00 per basic and diluted share a year ago. LBITDA was $44.146 million against $38.577 million a year ago. Adjusted EBITDA was $7.160 million against LBITDA of $11.542 million a year ago. Pro forma adjusted EBITDA per share diluted was $0.07 against LBITDA of $0.15 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $18.59 USD +0.20

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $163.41 USD +2.99
MorphoSys AG €73.76 EUR -1.72
XOMA Corp $4.57 USD +0.06
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.4x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 50.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.